Evidence map›Paper›PMID 40323333›Full record

ArticleDiabetologia2025

Correction: Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial.

Ildiko Lingvay, Malik Benamar, Liming Chen, Ariel Fu, Esteban Jódar, Tomoyuki Nishida, Jean-Pierre Riveline, Daisuke Yabe, Thomas Zueger, Rosângela Réa

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Ildiko LingvayEndocrinology Division, Department of Internal Medicine and Peter O'Donnell Jr School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX, USA. Ildiko.Lingvay@UTSouthwestern.edu.ORCID http://orcid.org/0000-0001-7006-7401
Malik BenamarNovo Nordisk A/S, Søborg, Denmark.ORCID http://orcid.org/0009-0001-1820-1527
Liming ChenNHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital and Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China.ORCID http://orcid.org/0000-0002-5682-2340
Ariel FuNovo Nordisk A/S, Søborg, Denmark.ORCID http://orcid.org/0009-0007-0220-5877
Esteban JódarUniversitary Hospital QuironSalud Madrid, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain.ORCID http://orcid.org/0000-0002-1234-8560
Tomoyuki NishidaNovo Nordisk Pharma Ltd, Tokyo, Japan.ORCID http://orcid.org/0009-0004-5812-7167
Jean-Pierre RivelineDepartment of Endocrinology and Diabetology, Lariboisiere Hospital, APHP, Paris-Cite University Paris, Paris, France.ORCID http://orcid.org/0000-0001-7991-0741
Daisuke YabeDepartment of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan.ORCID http://orcid.org/0000-0002-5334-7687
Thomas ZuegerDepartment of Endocrinology, Diabetes and Metabolic Diseases, Kantonsspital Olten, Olten, Switzerland.ORCID http://orcid.org/0000-0001-6190-7405
Rosângela RéaInternal Medicine Department, Endocrine Division (SEMPR), Universidade Federal do Parana, Curitiba, Brazil.ORCID http://orcid.org/0000-0002-2102-0495

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40323333
PMCPMC12176977

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.